{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:32:23Z","timestamp":1770813143615,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s12020-015-0754-z","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T08:19:43Z","timestamp":1443514783000},"page":"526-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["How to manage pasireotide, when using as medical treatment for Cushing\u2019s disease"],"prefix":"10.1007","volume":"50","author":[{"given":"Stephan","family":"Petersenn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"issue":"6","key":"754_CR1","doi-asserted-by":"crossref","first-page":"R227","DOI":"10.1530\/EJE-14-0883","volume":"172","author":"S Petersenn","year":"2015","unstructured":"S. Petersenn, A. Beckers, D. Ferone, A. van der Lely, J. Bollerslev, M. Boscaro, T. Brue, P. Bruzzi, F.F. Casanueva, P. Chanson, A. Colao, M. Reincke, G. Stalla, S. Tsagarakis, Therapy of endocrine disease: outcomes in patients with Cushing\u2019s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur. J. Endocrinol. 172(6), R227\u2013R239 (2015). doi: 10.1530\/EJE-14-0883","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"754_CR2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","volume":"165","author":"E Valassi","year":"2011","unstructured":"E. Valassi, A. Santos, M. Yaneva, M. Toth, C.J. Strasburger, P. Chanson, J.A. Wass, O. Chabre, M. Pfeifer, R.A. Feelders, S. Tsagarakis, P.J. Trainer, H. Franz, K. Zopf, S. Zacharieva, S.W. Lamberts, A. Tabarin, S.M. Webb, E.S. Group, The European Registry on Cushing\u2019s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur. J. Endocrinol. 165(3), 383\u2013392 (2011). doi: 10.1530\/EJE-11-0272","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"754_CR3","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, B.S.G. Pasireotide, A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N. Engl. J. Med. 366(10), 914\u2013924 (2012). doi: 10.1056\/NEJMoa1105743","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"754_CR4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"R. Pivonello, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, A. Trovato, G. Hughes, L.R. Salgado, A. Lacroix, J. Schopohl, B.M. Biller, B.S.G. Pasireotide, Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study. Clin. Endocrinol. (Oxf) 81(3), 408\u2013417 (2014). doi: 10.1111\/cen.12431","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"1","key":"754_CR5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-13-1013","volume":"171","author":"SM Webb","year":"2014","unstructured":"S.M. Webb, J.E. Ware, A. Forsythe, M. Yang, X. Badia, L.M. Nelson, J.E. Signorovitch, L. McLeod, M. Maldonado, W. Zgliczynski, C. de Block, L. Portocarrero-Ortiz, M. Gadelha, Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing\u2019s disease. Eur. J. Endocrinol. 171(1), 89\u201398 (2014). doi: 10.1530\/EJE-13-1013","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"754_CR6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","volume":"18","author":"J Schopohl","year":"2015","unstructured":"J. Schopohl, F. Gu, R. Rubens, L. Van Gaal, J. Bertherat, M. Ligueros-Saylan, A. Trovato, G. Hughes, L.R. Salgado, M. Boscaro, R. Pivonello, Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing\u2019s disease: results from an open-ended, open-label extension trial. Pituitary 18(5), 604\u2013612 (2015). doi: 10.1007\/s11102-014-0618-1","journal-title":"Pituitary"},{"key":"754_CR7","author":"C Simeoli","year":"2015","unstructured":"C. Simeoli, R.S. Auriemma, F. Tortora, M. De Leo, D. Iacuaniello, A. Cozzolino, M.C. De Martino, C. Pivonello, C.G. Mainolfi, R. Rossi, S. Cirillo, A. Colao, R. Pivonello, The treatment with pasireotide in Cushing\u2019s disease: effects of long-term treatment on tumor mass in the experience of a single center. Endocrine (2015). doi: 10.1007\/s12020-015-0557-2","journal-title":"Endocrine"},{"issue":"5","key":"754_CR8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1210\/jc.2013-1497","volume":"98","author":"L Katznelson","year":"2013","unstructured":"L. Katznelson, Sustained improvements in plasma ACTH and clinical status in a patient with Nelson\u2019s syndrome treated with pasireotide LAR, a multireceptor somatostatin analog. J. Clin. Endocrinol. Metab. 98(5), 1803\u20131807 (2013). doi: 10.1210\/jc.2013-1497","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"754_CR9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1177\/0091270011408727","volume":"52","author":"S Petersenn","year":"2012","unstructured":"S. Petersenn, N. Unger, K. Hu, B. Weisshaar, Y. Zhang, E. Bouillaud, K.H. Resendiz, Y. Wang, K. Mann, Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers. J. Clin. Pharmacol. 52(7), 1017\u20131027 (2012). doi: 10.1177\/0091270011408727","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"754_CR10","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"R.R. Henry, T.P. Ciaraldi, D. Armstrong, P. Burke, M. Ligueros-Saylan, S. Mudaliar, Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J. Clin. Endocrinol. Metab. 98(8), 3446\u20133453 (2013). doi: 10.1210\/jc.2013-1771","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"754_CR11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","volume":"103","author":"A Breitschaft","year":"2014","unstructured":"A. Breitschaft, K. Hu, K.H. Resendiz, C. Darstein, G. Golor, Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res. Clin. Pract. 103(3), 458\u2013465 (2014). doi: 10.1016\/j.diabres.2013.12.011","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"2","key":"754_CR12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","volume":"17","author":"A Colao","year":"2014","unstructured":"A. Colao, C. De Block, M.S. Gaztambide, S. Kumar, J. Seufert, F.F. Casanueva, Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2), 180\u2013186 (2014). doi: 10.1007\/s11102-013-0483-3","journal-title":"Pituitary"},{"issue":"1","key":"754_CR13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11102-014-0557-x","volume":"18","author":"L Trementino","year":"2015","unstructured":"L. Trementino, M. Cardinaletti, C. Concettoni, G. Marcelli, B. Polenta, M. Spinello, M. Boscaro, G. Arnaldi, Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing\u2019s disease. Pituitary 18(1), 60\u201367 (2015). doi: 10.1007\/s11102-014-0557-x","journal-title":"Pituitary"},{"issue":"1","key":"754_CR14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12020-014-0499-0","volume":"50","author":"L Trementino","year":"2015","unstructured":"L. Trementino, M. Zilio, G. Marcelli, G. Michetti, M. Barbot, F. Ceccato, M. Boscaro, C. Scaroni, G. Arnaldi, The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing\u2019s disease: findings from a pilot study. Endocrine 50(1), 154\u2013161 (2015). doi: 10.1007\/s12020-014-0499-0","journal-title":"Endocrine"},{"issue":"6","key":"754_CR15","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2265.2005.02278.x","volume":"62","author":"JA Gilbert","year":"2005","unstructured":"J.A. Gilbert, J.P. Miell, S.M. Chambers, A.M. McGregor, S.J. Aylwin, The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin. Endocrinol. (Oxf) 62(6), 742\u2013747 (2005). doi: 10.1111\/j.1365-2265.2005.02278.x","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"3","key":"754_CR16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.2004.02191.x","volume":"62","author":"N Karavitaki","year":"2005","unstructured":"N. Karavitaki, I. Botusan, S. Radian, M. Coculescu, H.E. Turner, J.A. Wass, The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin. Endocrinol. (Oxf) 62(3), 282\u2013288 (2005). doi: 10.1111\/j.1365-2265.2004.02191.x","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"1","key":"754_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/eje.1.01935","volume":"153","author":"WW Herder de","year":"2005","unstructured":"W.W. de Herder, H.R. Taal, P. Uitterlinden, R.A. Feelders, J.A. Janssen, A.J. van der Lely, Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur. J. Endocrinol. 153(1), 67\u201371 (2005). doi: 10.1530\/eje.1.01935","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"754_CR18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11102-013-0503-3","volume":"17","author":"M Boscaro","year":"2014","unstructured":"M. Boscaro, J. Bertherat, J. Findling, M. Fleseriu, A.B. Atkinson, S. Petersenn, J. Schopohl, P. Snyder, G. Hughes, A. Trovato, K. Hu, M. Maldonado, B.M. Biller, Extended treatment of Cushing\u2019s disease with pasireotide: results from a 2-year, Phase II study. Pituitary 17(4), 320\u2013326 (2014). doi: 10.1007\/s11102-013-0503-3","journal-title":"Pituitary"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-015-0754-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-015-0754-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-015-0754-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:57:13Z","timestamp":1559440633000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-015-0754-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s12020-015-0754-z","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]}}}